Metabolomics for clinical use and research in chronic kidney disease

Nature Reviews Nephrology

Volumn 13, Issue 5, 2017, Pages 269-284

  Hocher, Berthold ^a   Adamski, Jerzy ^b  

^a HUNAN UNIVERSITY   (China)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; 6 N,N' DIMETHYLARGININE; ACICLOVIR; ACYLCARNITINE; ALPHA AMINO ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARISTOLOCHIC ACID; BIOLOGICAL MARKER; C MANNOSYLTRYPTOPHAN; CITRIC ACID; DIMETHYLARGININE; GLYCEROLIPID; IRBESARTAN; LIPID; META CRESOL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; POLYAMINE; PSEUDOURIDINE; STEROID; TOXIN; TRYPTOPHAN; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; UREA; URIC ACID; ARGININE; CARNITINE;

BIOINFORMATICS; CHRONIC KIDNEY FAILURE; CITRIC ACID CYCLE; CLINICAL RESEARCH; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MASS SPECTROMETRY; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STATISTICAL ANALYSIS; STRESS; UREA CYCLE; ANALOGS AND DERIVATIVES; BLOOD; LIPID METABOLISM; MEDICAL RESEARCH; METABOLISM; PROCEDURES;

ARGININE; BIOMARKERS; BIOMEDICAL RESEARCH; CARNITINE; DIABETES MELLITUS; HUMANS; LIPID METABOLISM; METABOLOMICS; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85015633317     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2017.30     Document Type: Review

References (193)

1. Zhang, Q. L. & Rothenbacher, D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8, 117 (2008).
2. Jha, V., Wang, A. Y. & Wang, H. The impact of CKD identification in large countries: the burden of illness. Nephrol. Dial. Transplant. 27 (Suppl. 3), iii32-iii38 (2012).
3. Stevens, P. E., Levin, A. & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825-830 (2013).
4. KDiGO. KDiGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 4 (2013).
5. Ferguson, T. W., Komenda, P. & Tangri, N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr. Opin. Nephrol. Hypertens. 24, 295-300 (2015).
6. Bokenkamp, A., van Wijk, J. A., Lentze, M. J. & Stoffel-Wagner, B. Effect of corticosteroid therapy on serum cystatin C and beta2?microglobulin concentrations. Clin. Chem. 48, 1123-1126 (2002).
7. Knight, E. L. et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65, 1416-1421 (2004).
8. Fricker, M., Wiesli, P., Brandle, M., Schwegler, B. & Schmid, C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 63, 1944-1947 (2003).
9. Wan, Z. et al. Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute?on?chronic liver failure. PLoS ONE 10, e0116968 (2015).
10. Ichikawa, D. et al. Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion. Nephrology (Carlton) http://dx.doi.org/10.1111/nep.12998 (2017).
11. Foster, M. C. et al. Urinary biomarkers and risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin. J. Am. Soc. Nephrol. 10, 1956-1963 (2015).
12. Peralta, C. A. et al. Associations of urinary levels of kidney injury molecule 1 (KIM?1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am. J. Kidney Dis. 60, 904-911 (2012).
13. Levin, A., Lancashire, W. & Fassett, R. G. Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. Kidney Int. 83, 1001-1009 (2013).
14. Tweeddale, H., Notley-McRobb, L. & Ferenci, T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool (metabolome) analysis. J. Bacteriol. 180, 5109-5116 (1998).
15. Nicholson, J. K., Lindon, J. C. & Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
16. Su, L. J. et al. The use of metabolomics in populationbased research. Adv. Nutr. 5, 785-788 (2014).
17. Griffin, J. L. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Phil. Trans. R. Soc. B 361, 147-161 (2006).
18. Lindon, J. C. & Nicholson, J. K. The emergent role of metabolic phenotyping in dynamic patient stratification. Expert Opin. Drug Metab. Toxicol. 10, 915-919 (2014).
19. Fahy, E., Sud, M., Cotter, D. & Subramaniam, S. LIPID MAPS online tools for lipid research. Nucleic Acids Res. 35, W606-W612 (2007).
20. Wishart, D. S. et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 37, D603-D610 (2009).
21. Zamboni, N., Saghatelian, A. & Patti, G. J. Defining the metabolome: size, flux, and regulation. Mol. Cell 58, 699-706 (2015).
22. Huang, D. et al. An integrated plasma and urinary metabonomic study using UHPLC?MS: intervention effects of Epimedium koreanum on 'Kidney-Yang Deficiency syndrome' rats. J. Pharm. Biomed. Anal. 76, 200-206 (2013).
23. Yousri, N. A. et al. A systems view of type 2 diabetesassociated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic control. Diabetologia 58, 1855-1867 (2015).
24. Krug, S. et al. The dynamic range of the human metabolome revealed by challenges. FASEB J. 26, 2607-2619 (2012).
25. Floegel, A. et al. Reliability of serum metabolite concentrations over a 4?month period using a targeted metabolomic approach. PLoS ONE 6, e21103 (2011).
26. Yousri, N. A. et al. Long term conservation of human metabolic phenotypes and link to heritability. Metabolomics 10, 1005-1017 (2014).
27. Mook-Kanamori, D. O. et al. Type 2 diabetes is associated with postprandial amino acid measures. Arch. Biochem. Biophys. 589, 138-144 (2016).
28. Jacobs, S. et al. Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPICPotsdam Study. Am. J. Clin. Nutr. 100, 891-900 (2014).
29. Xu, T. et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med. 11, 60 (2013).
30. Lankinen, M. et al. Metabolomic analysis of plasma metabolites that may mediate effects of rye bread on satiety and weight maintenance in postmenopausal women. J. Nutr. 141, 31-36 (2011).
31. Jaremek, M. et al. Alcohol-induced metabolomic differences in humans. Transl Psychiatry 3, e276 (2013).
32. Yu, Z. et al. Human serum metabolic profiles are age dependent. Aging Cell 11, 960-967 (2012).
33. Menni, C. et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. Int. J. Epidemiol. 42, 1111-1119 (2013).
34. Asher, G. & Sassone-Corsi, P. Time for food: the intimate interplay between nutrition, metabolism, and the circadian clock. Cell 161, 84-92 (2015).
35. Guo, L. et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc. Natl Acad. Sci. USA 112, E4901-E4910 (2015).
36. Heinzmann, S. S. et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. J. Proteome Res. 11, 643-655 (2012).
37. Hyotylainen, T. Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications. Expert Rev. Mol. Diagn. 12, 527-538 (2012).
38. Whitfield, P. D., German, A. J. & Noble, P. J. Metabolomics: an emerging post-genomic tool for nutrition. Br. J. Nutr. 92, 549-555 (2004).
39. Gebregiworgis, T. & Powers, R. Application of NMR metabolomics to search for human disease biomarkers. Comb. Chem. High Throughput Screen. 15, 595-610 (2012).
40. Artati, A., Prehn, C., Möller, G. & Adamski, J. in Genetics Meets Metabolomics: From Experiment to Systems Biology (ed. Suhre, K.) 13-38 (Springer, 2012).
41. Baldwin, M. A. Mass spectrometers for the analysis of biomolecules. Methods Enzymol. 402, 3-48 (2005).
42. Hopfgartner, G. et al. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules. J. Mass Spectrom. 39, 845-855 (2004).
43. Khamis, M. M., Adamko, D. J. & El?Aneed, A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom. Rev. 36, 115-134 (2017).
44. Campbell, J. L. & Le Blanc, J. C. Using high-resolution quadrupole TOF technology in DMPK analyses. Bioanalysis 4, 487-500 (2012).
45. Evans, A. M., DeHaven, C. D., Barrett, T., Mitchell, M. & Milgram, E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the smallmolecule complement of biological systems. Anal. Chem. 81, 6656-6667 (2009).
46. Cacciatore, S. & Loda, M. Innovation in metabolomics to improve personalized healthcare. Ann. NY Acad. Sci. 1346, 57-62 (2015).
47. Nicolardi, S., Bogdanov, B., Deelder, A. M., Palmblad, M. & van der Burgt, Y. E. Developments in FTICR?MS and its potential for body fluid signatures. Int. J. Mol. Sci. 16, 27133-27144 (2015).
48. Suhre, K. et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 54-60 (2011).
49. Hirayama, A. et al. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal. Bioanal. Chem. 404, 3101-3109 (2012).
50. Tsutsui, H. et al. Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultraperformance liquid chromatography with electrospray ionization time?of?flight mass spectrometry. Clin. Chim. Acta 412, 861-872 (2011).
51. Krumsiek, J. et al. Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information. PLoS Genet. 8, e1003005 (2012).
52. Psychogios, N. et al. The human serum metabolome. PLoS ONE 6, e16957 (2011).
53. Bouatra, S. et al. The human urine metabolome. PLoS ONE 8, e73076 (2013).
54. Klepacki, J., Klawitter, J., Klawitter, J., Thurman, J. M. & Christians, U. A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine. Clin. Chim. Acta 446, 43-53 (2015).
55. Rhee, E. P. Metabolomics and renal disease. Curr. Opin. Nephrol. Hypertens. 24, 371-379 (2015).
56. Zhang, A., Sun, H., Qiu, S. & Wang, X. Metabolomics insights into pathophysiological mechanisms of nephrology. Int. Urol. Nephrol. 46, 1025-1030 (2014).
57. Schena, F. P. Biomarkers and personalized therapy in chronic kidney diseases. Expert Opin. Investig. Drugs 23, 1051-1054 (2014).
58. Bartel, J., Krumsiek, J. & Theis, F. J. Statistical methods for the analysis of high-throughput metabolomics data. Comput. Struct. Biotechnol. J. 4, e201301009 (2013).
59. Issaq, H. J., Van, Q. N., Waybright, T. J., Muschik, G. M. & Veenstra, T. D. Analytical and statistical approaches to metabolomics research. J. Sep. Sci. 32, 2183-2199 (2009).
60. Armitage, E. G., Godzien, J., Alonso-Herranz, V., Lopez-Gonzalvez, A. & Barbas, C. Missing value imputation strategies for metabolomics data. Electrophoresis 36, 3050-3060 (2015).
61. Succop, P. A., Clark, S., Chen, M. & Galke, W. Imputation of data values that are less than a detection limit. J. Occup. Environ. Hyg. 1, 436-441 (2004).
62. Berk, M., Ebbels, T. & Montana, G. A statistical framework for biomarker discovery in metabolomic time course data. Bioinformatics 27, 1979-1985 (2011).
63. Wartenberg, D. & Northridge, M. Defining exposure in case-control studies: a new approach. Am. J. Epidemiol. 133, 1058-1071 (1991).
64. Kruskal, W. H. & Wallis, W. A. Use of ranks in onecriterion variance analysis. J. Am. Stat. Assoc. 47, 583-621 (1952).
65. Mann, H. B. & Whitney, D. R. On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18, 50-60 (1947).
66. Xia, J., Broadhurst, D. I., Wilson, M. & Wishart, D. S. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9, 280-299 (2013).
67. Lopez-Giacoman, S. & Madero, M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J. Nephrol. 4, 57-73 (2015).
68. Fassett, R. G. et al. Biomarkers in chronic kidney disease: a review. Kidney Int. 80, 806-821 (2011).
69. Breit, M. & Weinberger, K. M. Metabolic biomarkers for chronic kidney disease. Arch. Biochem. Biophys. 589, 62-80 (2016).
70. Zhang, Z. H. et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J. Proteome Res. 15, 3802-3812 (2016).
71. Fleck, C. et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int. Suppl. 78, S14-S18 (2001).
72. Wahbi, N. et al. Dimethylarginines in chronic renal failure. J. Clin. Pathol. 54, 470-473 (2001).
73. Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575 (1992).
74. Raptis, V., Kapoulas, S. & Grekas, D. Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton) 18, 11-21 (2013).
75. Notsu, Y., Yano, S., Shibata, H., Nagai, A. & Nabika, T. Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. Atherosclerosis 239, 61-66 (2015).
76. Neri, M. et al. A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. Cephalalgia 35, 931-937 (2015).
77. Trgo, G. et al. Association of asymmetric dimethylarginine with acute pancreatitis-induced hyperglycemia. Pancreas 45, 694-699 (2016).
78. Aydemir, O., Ozcan, B., Yucel, H., Yagmur Bas, A. & Demirel, N. Asymmetric dimethylarginine and L?arginine levels in neonatal sepsis and septic shock. J. Matern. Fetal Neonatal Med. 28, 977-982 (2015).
79. Tomlinson, J. A. et al. Reduced renal methylarginine metabolism protects against progressive kidney damage. J. Am. Soc. Nephrol. 26, 3045-3059 (2015).
80. Wurtman, R. J., Larin, F., Axelrod, J., Shein, H. M. & Rosasco, K. Formation of melatonin and 5?hydroxyindole acetic acid from 14C?tryptophan by rat pineal glands in organ culture. Nature 217, 953-954 (1968).
81. Udenfriend, S., Weissbach, H. & Bogdanski, D. F. Increase in tissue serotonin following administration of its precursor 5?hydroxytryptophan. J. Biol. Chem. 224, 803-810 (1957).
82. Hankes, L. V., Brown, R. R. & Schmaeler, M. Metabolism of isomers of 3?hydroxykynureninec14 to quinolinic acid, niacin metabolites and carbon dioxide. Proc. Soc. Exp. Biol. Med. 121, 253-259 (1966).
83. Saito, K. et al. Mechanism of increases in L?kynurenine and quinolinic acid in renal insufficiency. Am. J. Physiol. Renal Physiol. 279, F565-F572 (2000).
84. Schefold, J. C. et al. Increased indoleamine 2,3?dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol. Dial. Transplant. 24, 1901-1908 (2009).
85. Streja, E. et al. Niacin and progression of CKD. Am. J. Kidney Dis. 65, 785-798 (2015).
86. Bryan, G. T. Quantitative studies on the urinary excretion of indoxyl sulfate (indican) in man following administration of L?tryptophan and acetyl-L?tryptophan. Am. J. Clin. Nutr. 19, 105-112 (1966).
87. Niwa, T. Uremic toxicity of indoxyl sulfate. Nagoya J. Med. Sci. 72, 1-11 (2010).
88. Sudar-Milovanovic, E. et al. Hormonal regulation of nitric oxide (NO) in cardio-metabolic diseases. Curr. Pharm. Des. http://dx.doi.org/10.2174/1381612823 666170124124855 (2017).
89. Persichini, T. et al. Cross-talk between NO synthase isoforms in neuro-inflammation: possible implications in HIV-associated neurocognitive disorders. Curr. Med. Chem. 23, 2706-2714 (2016).
90. Ghimire, K., Altmann, H. M., Straub, A. & Isenberg, J. S. Nitric oxide: what's new to NO? Am. J. Physiol. Cell Physiol. http://dx.doi.org/10.1152/ajpcell.00315.2016 (2016).
91. Erkens, R. et al. Modulation of local and systemic heterocellular communication by mechanical forces: a role of eNOS. Antioxid. Redox Signal. http://dx.doi. org/10.1089/ars.2016.6904 (2016).
92. Leiper, J. & Vallance, P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43, 542-548 (1999).
93. Baylis, C. Nitric oxide deficiency in chronic kidney disease. Am. J. Physiol. Renal Physiol. 294, F1-F9 (2008).
94. Popolo, A., Adesso, S., Pinto, A., Autore, G. & Marzocco, S. L?Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids 46, 2271-2286 (2014).
95. Pegg, A. E. The function of spermine. IUBMB Life 66, 8-18 (2014).
96. Ramani, D., De Bandt, J. P. & Cynober, L. Aliphatic polyamines in physiology and diseases. Clin. Nutr. 33, 14-22 (2014).
97. Saito, A., Takagi, T., Chung, T. G. & Ohta, K. Serum levels of polyamines in patients with chronic renal failure. Kidney Int. Suppl. 16, S234-S237 (1983).
98. Goek, O. N. et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol. Dial. Transplant. 28, 2131-2138 (2013).
99. Rroji, M. et al. Association of advanced age with concentrations of uraemic toxins in CKD. J. Nephrol. 29, 81-91 (2016).
100. Shah, V. O. et al. Plasma metabolomic profiles in different stages of CKD. Clin. J. Am. Soc. Nephrol. 8, 363-370 (2013).
101. Duranton, F. et al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin. J. Am. Soc. Nephrol. 9, 37-45 (2014).
102. Liu, J. et al. 1H NMR-based metabonomic analysis of serum and urine in a nonhuman primate model of diabetic nephropathy. Mol. Biosyst. 9, 2645-2652 (2013).
103. Choi, J. Y. et al. Dialysis modality-dependent changes in serum metabolites: accumulation of inosine and hypoxanthine in patients on haemodialysis. Nephrol. Dial. Transplant. 26, 1304-1313 (2011).
104. Abbiss, H. et al. Development of a non-targeted metabolomics method to investigate urine in a rat model of polycystic kidney disease. Nephrology (Carlton) 17, 104-110 (2012).
105. Riehle, R. D., Cornea, S. & Degterev, A. Role of phosphatidylinositol 3,4,5?trisphosphate in cell signaling. Adv. Exp. Med. Biol. 991, 105-139 (2013).
106. Wakelam, M. J., Pettitt, T. R. & Postle, A. D. Lipidomic analysis of signaling pathways. Methods Enzymol. 432, 233-246 (2007).
107. Serhan, C. N., Haeggstrom, J. Z. & Leslie, C. C. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 10, 1147-1158 (1996).
108. Chaurasia, B. & Summers, S. A. Ceramides-lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 26, 538-550 (2015).
109. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol. 15, 511-523 (2015).
110. Wurtz, P. et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131, 774-785 (2015).
111. Wang-Sattler, R. et al. Novel biomarkers for prediabetes identified by metabolomics. Mol. Syst. Biol. 8, 615 (2012).
112. Vouk, K. et al. Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Hum. Reprod. 27, 2955-2965 (2012).
113. Albrecht, E. et al. Metabolite profiling reveals new insights into the regulation of serum urate in humans. Metabolomics 10, 141-151 (2014).
114. Goek, O. N. et al. Serum metabolite concentrations and decreased GFR in the general population. Am. J. Kidney Dis. 60, 197-206 (2012).
115. Fahy, E. et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 50 (Suppl.), S9-S14 (2009).
116. Pearson, D. J. & Tubbs, P. K. Acetyl-carnitine in heart and liver. Nature 202, 91 (1964).
117. Guder, W. G. & Wagner, S. The role of the kidney in carnitine metabolism. J. Clin. Chem. Clin. Biochem. 28, 347-350 (1990).
118. Bernard, A., Rigault, C., Mazue, F., Le Borgne, F. & Demarquoy, J. L?Carnitine supplementation and physical exercise restore age-associated decline in some mitochondrial functions in the rat. J. Gerontol. A Biol. Sci. Med. Sci. 63, 1027-1033 (2008).
119. Pescosolido, N., Imperatrice, B. & Karavitis, P. The aging eye and the role of L?carnitine and its derivatives. Drugs R. D. 9 (Suppl. 1), 3-14 (2008).
120. Zambrano, S. et al. The renoprotective effect of L?carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression. Eur. J. Nutr. 52, 1649-1659 (2013).
121. Bremer, J. Carnitine as a fatty acid carrier in intermediary metabolism. Nature 196, 993-994 (1962).
122. Pande, S. V. A mitochondrial carnitine acylcarnitine translocase system. Proc. Natl Acad. Sci. USA 72, 883-887 (1975).
123. Ferrara, F., Bertelli, A. & Falchi, M. Evaluation of carnitine, acetylcarnitine and isovalerylcarnitine on immune function and apoptosis. Drugs Exp. Clin. Res. 31, 109-114 (2005).
124. Mutomba, M. C. et al. Regulation of the activity of caspases by L?carnitine and palmitoylcarnitine. FEBS Lett. 478, 19-25 (2000).
125. Roe, C. R. et al. Isolated isobutyryl-CoA dehydrogenase deficiency: an unrecognized defect in human valine metabolism. Mol. Genet. Metab. 65, 264-271 (1998).
126. Miller, W. L. Steroid hormone synthesis in mitochondria. Mol. Cell. Endocrinol. 379, 62-73 (2013).
127. Prehn, C., Möller, G. & Adamski, J. Recent advances in 17beta?hydroxysteroid dehydrogenases. J. Steroid Biochem. Mol. Biol. 114, 72-77 (2009).
128. Labrie, F. Intracrinology in action: importance of extragonadal sex steroid biosynthesis and inactivation in peripheral tissues in both women and men. J. Steroid Biochem. Mol. Biol. 145, 131-132 (2015).
129. Chapman, K. E. et al. Changing glucocorticoid action: 11beta?hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation. J. Steroid Biochem. Mol. Biol. 137, 82-92 (2013).
130. Hardy, M. P. et al. Stress hormone and male reproductive function. Cell Tissue Res. 322, 147-153 (2005).
131. Morton, N. M. et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta?hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276, 41293-41300 (2001).
132. Draper, N. & Stewart, P. M. 11beta?hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol. 186, 251-271 (2005).
133. Kotelevtsev, Y. et al. 11hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl Acad. Sci. USA 94, 14924-14929 (1997).
134. You, Y. H., Quach, T., Saito, R., Pham, J. & Sharma, K. Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease. J. Am. Soc. Nephrol. 27, 466-481 (2016).
135. Li, M. et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 304, F1317-F1324 (2013).
136. Hasselwander, O. & Young, I. S. Oxidative stress in chronic renal failure. Free Radic. Res. 29, 1-11 (1998).
137. Himmelfarb, J., Stenvinkel, P., Ikizler, T. A. & Hakim, R. M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 62, 1524-1538 (2002).
138. Chen, H. et al. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol. 10, 168-178 (2016).
139. Mashima, R., Nakanishi-Ueda, T. & Yamamoto, Y. Simultaneous determination of methionine sulfoxide and methionine in blood plasma using gas chromatography-mass spectrometry. Anal. Biochem. 313, 28-33 (2003).
140. Breier, M. et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma samples. PLoS ONE 9, e89728 (2014).
141. Simic-Ogrizovic, S. et al. Markers of oxidative stress after renal transplantation. Transpl. Int. 11 (Suppl. 1), S125-S129 (1998).
142. Fonseca, I. et al. Oxidative stress in kidney transplantation: malondialdehyde is an early predictive marker of graft dysfunction. Transplantation 97, 1058-1065 (2014).
143. Akanuma, H., Ogawa, K., Lee, Y. & Akanuma, Y. Reduced levels of plasma 1,5?anhydroglucitol in diabetic patients. J. Biochem. 90, 157-162 (1981).
144. Kametani, S., Hashimoto, Y., Yamanouchi, T., Akanuma, Y. & Akanuma, H. Reduced renal reabsorption of 1,5?anhydro-D?glucitol in diabetic rats and mice. J. Biochem. 102, 1599-1607 (1987).
145. Yu, B. et al. Serum metabolomic profiling and incident CKD among African Americans. Clin. J. Am. Soc. Nephrol. 9, 1410-1417 (2014).
146. Dooms-Goossens, A., Degreef, H., Vanhee, J., Kerkhofs, L. & Chrispeels, M. T. Chlorocresol and chloracetamide: allergens in medications, glues, and cosmetics. Contact Dermatitis 7, 51-52 (1981).
147. Sanders, J. M. et al. Carcinogenesis studies of cresols in rats and mice. Toxicology 257, 33-39 (2009).
148. Ford, S. M., Hook, J. B. & Bond, J. T. The effects of butylated hydroxyanisole and butylated hydroxytoluene on renal function in the rat. I. Effects on fluid and electrolyte excretion. Food Cosmet Toxicol. 18, 15-20 (1980).
149. De Smet, R. et al. Toxicity of free p?cresol: a prospective and cross-sectional analysis. Clin. Chem. 49, 470-478 (2003).
150. Lin, H. H., Huang, C. C., Lin, T. Y. & Lin, C. Y. p?Cresol mediates autophagic cell death in renal proximal tubular cells. Toxicol. Lett. 234, 20-29 (2015).
151. Brocca, A., Virzi, G. M., de Cal, M., Cantaluppi, V. & Ronco, C. Cytotoxic effects of p?cresol in renal epithelial tubular cells. Blood Purif. 36, 219-225 (2013).
152. Adamski, J. Genome-wide association studies with metabolomics. Genome Med. 4, 34 (2012).
153. Sekula, P. et al. A metabolome-wide association study of kidney function and disease in the general population. J. Am. Soc. Nephrol. 27, 1175-1188 (2016).
154. Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009).
155. Rhee, E. P. et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J. Am. Soc. Nephrol. 24, 1330-1338 (2013).
156. Gao, X. et al. Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst. Biol. 6 (Suppl. 1), S14 (2012).
157. Mutsaers, H. A. et al. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients. PLoS ONE 8, e71199 (2013).
158. Hao, X. et al. Distinct metabolic profile of primary focal segmental glomerulosclerosis revealed by NMRbased metabolomics. PLoS ONE 8, e78531 (2013).
159. Posada-Ayala, M. et al. Identification of a urine metabolomic signature in patients with advancedstage chronic kidney disease. Kidney Int. 85, 103-111 (2014).
160. Pena, M. J. et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet. Med. 31, 1138-1147 (2014).
161. Sharma, K. et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol. 24, 1901-1912 (2013).
162. van der Kloet, F. M. et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms?based metabolomics (FinnDiane study). Metabolomics 8, 109-119 (2012).
163. Lee, J. et al. Changes in serum metabolites with the stage of chronic kidney disease: comparison of diabetes and non-diabetes. Clin. Chim. Acta 459, 123-131 (2016).
164. Gao, Y. et al. Identifying early urinary metabolic changes with long-term environmental exposure to cadmium by mass-spectrometry-based metabolomics. Environ. Sci. Technol. 48, 6409-6418 (2014).
165. Uehara, T. et al. Identification of metabolomic biomarkers for drug-induced acute kidney injury in rats. J. Appl. Toxicol. 34, 1087-1095 (2014).
166. Sun, X. et al. Metabonomics evaluation of urine from rats administered with phorate under long-term and low-level exposure by ultra-performance liquid chromatography-mass spectrometry. J. Appl. Toxicol. 34, 176-183 (2014).
167. Zinellu, A. et al. Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. Nutr. Metab. Cardiovasc. Dis. 25, 153-159 (2015).
168. Vanhaelen, M., Vanhaelen-Fastre, R., But, P. & Vanherweghem, J. L. Identification of aristolochic acid in Chinese herbs. Lancet 343, 174 (1994).
169. Zhao, Y. Y. et al. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis 7, 685-700 (2015).
170. Zhao, Y. Y. et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci. Rep. 5, 12936 (2015).
171. Zhang, X. et al. Plasma metabolic profiling analysis of nephrotoxicity induced by acyclovir using metabonomics coupled with multivariate data analysis. J. Pharm. Biomed. Anal. 97, 151-156 (2014).
172. Hanna, M. H. et al. Urinary metabolomic markers of aminoglycoside nephrotoxicity in newborn rats. Pediatr. Res. 73, 585-591 (2013).
173. Wei, Q., Xiao, X., Fogle, P. & Dong, Z. Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. PLoS ONE 9, e106647 (2014).
174. Zhao, X., Chen, J., Ye, L. & Xu, G. Serum metabolomics study of the acute graft rejection in human renal transplantation based on liquid chromatography-mass spectrometry. J. Proteome Res. 13, 2659-2667 (2014).
175. Wettersten, H. I. et al. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res. 75, 2541-2552 (2015).
176. Floegel, A. et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62, 639-648 (2013).
177. Felig, P., Wahren, J., Sherwin, R. & Palaiologos, G. Amino acid and protein metabolism in diabetes mellitus. Arch. Intern. Med. 137, 507-513 (1977).
178. Wang, T. J. et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448-453 (2011).
179. Rhee, E. P. et al. Metabolomics of chronic kidney disease progression: a case-control analysis in the chronic renal insufficiency cohort study. Am. J. Nephrol. 43, 366-374 (2016).
180. Kimura, T. et al. Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling. Sci. Rep. 6, 26138 (2016).
181. Kobayashi, T. et al. A metabolomics-based approach for predicting stages of chronic kidney disease. Biochem. Biophys. Res. Commun. 445, 412-416 (2014).
182. Nkuipou-Kenfack, E. et al. Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE 9, e96955 (2014).
183. Mussap, M., Antonucci, R., Noto, A. & Fanos, V. The role of metabolomics in neonatal and pediatric laboratory medicine. Clin. Chim. Acta 426, 127-138 (2013).
184. Yin, P., Lehmann, R. & Xu, G. Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal. Bioanal. Chem. 407, 4879-4892 (2015).
185. Bernini, P. et al. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. J. Biomol. NMR 49, 231-243 (2011).
186. Anton, G. et al. Pre-analytical sample quality: metabolite ratios as an intrinsic marker for prolonged room temperature exposure of serum samples. PLoS ONE 10, e0121495 (2015).
187. Herberth, G. et al. Endogenous metabolites and inflammasome activity in early childhood and links to respiratory diseases. J. Allergy Clin. Immunol. 136, 495-497 (2015).
188. Viswan, A., Sharma, R. K., Azim, A. & Sinha, N. NMRbased metabolic snapshot from minibronchoalveolar lavage fluid: an approach to unfold human respiratory metabolomics. J. Proteome Res. 15, 302-310 (2016).
189. Tsentalovich, Y. P. et al. Metabolomic composition of normal aged and cataractous human lenses. Exp. Eye Res. 134, 15-23 (2015).
190. Courant, F., Antignac, J. P., Monteau, F. & Le Bizec, B. Metabolomics as a potential new approach for investigating human reproductive disorders. J. Proteome Res. 12, 2914-2920 (2013).
191. Lutz, U., Lutz, R. W. & Lutz, W. K. Metabolic profiling of glucuronides in human urine by LC?MS/MS and partial least-squares discriminant analysis for classification and prediction of gender. Anal. Chem. 78, 4564-4571 (2006).
192. Fonville, J. M., Richards, S. E., Barton, R. H., Boulange, C. L. & Ebbbels, T. M. D. The evolution of partial least square models and related chemometric approaches in metabonomics and metabolite phenotyping. J. Chemom. 24, 636-649 (2010).
193. Trygg, J. & Wold, S. Orthogonal projections to latent structures (OPLS). J. Chemom. 16, 119-128 (2002).